AU2009265278B2 - Camelid derived antigen binding polypeptides - Google Patents

Camelid derived antigen binding polypeptides Download PDF

Info

Publication number
AU2009265278B2
AU2009265278B2 AU2009265278A AU2009265278A AU2009265278B2 AU 2009265278 B2 AU2009265278 B2 AU 2009265278B2 AU 2009265278 A AU2009265278 A AU 2009265278A AU 2009265278 A AU2009265278 A AU 2009265278A AU 2009265278 B2 AU2009265278 B2 AU 2009265278B2
Authority
AU
Australia
Prior art keywords
domain
antigen binding
binding polypeptide
human
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009265278A
Other languages
English (en)
Other versions
AU2009265278A1 (en
Inventor
Christophe Frederic Jerome Blanchetot
Johannes Joesph Wilhelmus De Haard
Torsten Dreier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2009265278A1 publication Critical patent/AU2009265278A1/en
Application granted granted Critical
Publication of AU2009265278B2 publication Critical patent/AU2009265278B2/en
Assigned to ARGEN-X N.V. reassignment ARGEN-X N.V. Request to Amend Deed and Register Assignors: ARGEN-X B.V.
Assigned to ARGENX BVBA reassignment ARGENX BVBA Request for Assignment Assignors: ARGEN-X N.V.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2009265278A 2008-07-02 2009-07-02 Camelid derived antigen binding polypeptides Active AU2009265278B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7773008P 2008-07-02 2008-07-02
GB0812120A GB2461546B (en) 2008-07-02 2008-07-02 Antigen binding polypeptides
GB0812120.4 2008-07-02
US61/077,730 2008-07-02
US11016108P 2008-10-31 2008-10-31
US61/110,161 2008-10-31
PCT/IB2009/006329 WO2010001251A2 (en) 2008-07-02 2009-07-02 Antigen binding polypeptides

Publications (2)

Publication Number Publication Date
AU2009265278A1 AU2009265278A1 (en) 2010-01-07
AU2009265278B2 true AU2009265278B2 (en) 2015-03-19

Family

ID=39707916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009265278A Active AU2009265278B2 (en) 2008-07-02 2009-07-02 Camelid derived antigen binding polypeptides

Country Status (8)

Country Link
EP (2) EP3061768A1 (https=)
JP (1) JP6216940B2 (https=)
CN (2) CN107739405A (https=)
AU (1) AU2009265278B2 (https=)
CA (1) CA2728076C (https=)
DK (1) DK2310413T3 (https=)
GB (1) GB2461546B (https=)
WO (1) WO2010001251A2 (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
CN103620405B (zh) * 2010-12-31 2016-05-25 生物蛋白有限公司 全面单克隆抗体产生
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
IN2015DN00140A (https=) * 2012-08-31 2015-06-12 Argen X Bv
IN2015DN00138A (https=) * 2012-08-31 2015-06-12 Argen X Bv
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
ES2698976T3 (es) 2013-11-04 2019-02-06 Inst Nat Sante Rech Med Anticuerpo sintético de un solo dominio
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
WO2018103093A1 (zh) * 2016-12-09 2018-06-14 深圳华大基因研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
CN109206511B (zh) * 2018-09-13 2021-03-16 东南大学 能够特异结合HPVl6-E6蛋白的纳米抗体及其编码序列、制备方法和应用
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN114126646B (zh) * 2019-02-27 2025-05-30 浙江纳米抗体技术中心有限公司 基于序列的高通量方法产生骆驼抗体以高分辨率覆盖广泛表位
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JP2022548309A (ja) 2019-09-23 2022-11-17 ツイスト バイオサイエンス コーポレーション Ｃｒｔｈ２のバリアント核酸ライブラリー
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
CN110642948B (zh) * 2019-10-09 2021-06-29 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
JP7651477B2 (ja) * 2019-12-27 2025-03-26 株式会社カネカ プライマーセット及びそれを用いて標的核酸を検出する方法
GB202003444D0 (en) 2020-03-10 2020-04-22 argenx BV Musk agonist antibody
CN116284373B (zh) * 2020-08-14 2026-04-14 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN114591436B (zh) * 2020-12-07 2022-12-02 生物岛实验室 胃蛋白酶原i的特异性抗体及其制备方法与应用
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
KR20240133723A (ko) 2022-01-18 2024-09-04 아르제넥스 비브이 Fab 단편의 분무화
IL314367A (en) 2022-01-18 2024-09-01 argenx BV Antibodies to galectin 10
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
TW202504921A (zh) * 2023-02-28 2025-02-01 中國大陸商禮新醫藥科技（上海）有限公司 Ceacam5依賴性4-1bb促效性雙特異性抗體
KR20250155032A (ko) 2023-02-28 2025-10-29 라노바 메디신즈 리미티드 Ceacam5 의존적 4-1bb-작용성 이중특이적 항체
CN117310163B (zh) * 2023-11-23 2024-02-13 北京贝思泰生物科技有限公司 一种基于重组抗体的呼吸道合胞病毒检测方法
CN117986360B (zh) * 2024-02-01 2024-08-27 生物岛实验室 Il18蛋白的特异性抗体及其制备方法与应用
CN119591719B (zh) * 2024-11-25 2025-10-21 江苏集萃崛创生物科技研究所有限公司 靶向fap的纳米抗体、car-t细胞及其应用
CN119708213B (zh) * 2024-12-25 2025-12-12 河北科技师范学院 针对猪流行性腹泻病毒的纳米抗体或抗原结合片段及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032714A1 (en) * 1999-11-03 2001-05-10 King's College London Recombinant fusion molecules
WO2003025124A2 (en) * 2001-09-14 2003-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunoglobulin having particular framework scaffold and methods of making and using
WO2005037989A2 (en) * 2001-01-17 2005-04-28 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2006122825A2 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
WO2007136525A2 (en) * 2006-05-19 2007-11-29 Robert Webber Chimeric monoclonal antibody
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
WO2008070344A2 (en) * 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701578B2 (en) * 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032714A1 (en) * 1999-11-03 2001-05-10 King's College London Recombinant fusion molecules
WO2005037989A2 (en) * 2001-01-17 2005-04-28 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003025124A2 (en) * 2001-09-14 2003-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunoglobulin having particular framework scaffold and methods of making and using
WO2006122825A2 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
WO2007136525A2 (en) * 2006-05-19 2007-11-29 Robert Webber Chimeric monoclonal antibody
WO2008070344A2 (en) * 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
De Genst, E. et al. Developmental and Comparative Immunology 30 (2006) 187-198 *
Hamers-Casterman, C. et al. Nature, 1993, vol. 363, no. 6428, pp. 446-448 *

Also Published As

Publication number Publication date
WO2010001251A2 (en) 2010-01-07
EP3061768A1 (en) 2016-08-31
CN107739405A (zh) 2018-02-27
GB0812120D0 (en) 2008-08-06
WO2010001251A3 (en) 2010-03-11
CN102216328A (zh) 2011-10-12
JP6216940B2 (ja) 2017-10-25
CA2728076A1 (en) 2010-01-07
GB2461546B (en) 2010-07-07
EP2310413B1 (en) 2017-03-01
JP2011526493A (ja) 2011-10-13
CA2728076C (en) 2020-05-19
DK2310413T3 (en) 2017-06-06
AU2009265278A1 (en) 2010-01-07
EP2310413A2 (en) 2011-04-20
GB2461546A (en) 2010-01-06

Similar Documents

Publication Publication Date Title
AU2009265278B2 (en) Camelid derived antigen binding polypeptides
US9540437B2 (en) Humanized antibodies
US9221918B2 (en) Antigen binding polypeptides
WO2023161448A1 (en) Human-like target-binding proteins
IL210002A (en) Polypeptides that bind to antigen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ARGENX BVBA

Free format text: FORMER OWNER(S): ARGEN-X N.V.